54 results on '"Christgen M"'
Search Results
2. 120TiP Premenopausal women with breast cancer optimally treated with OFS (PROOFS)
3. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
4. Transmurale Nekrose des Fundus uteri nach septischem Abort – ein Fallbericht
5. HPV RNA analyses in sentinel and peripheral lymph nodes as potential diagnostic tool for metastatic cervical cancer
6. LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
7. Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
8. LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
9. Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18
10. Pathologische Komplettremissionsrate und Überleben von Patientinnen mit BRCA-assoziiertem triple-negativen Brustkrebs nach 12 Wochen anthrazyklinfreier neoadjuvanter Chemotherapie: Ergebnisse der WSG-ADAPT TN Studie (NCT01815242)
11. LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
12. Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial
13. LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results
14. 164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results
15. Resistenz gegenüber CD95-vermittelter Apoptose im duktalen Pankreasadenokarzinom: Die Rolle der Proteinkinase Cμ
16. ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer
17. Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial
18. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
19. Ektopien des Mammagewebes
20. Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial
21. Calziphylaxie der Mamma – eine seltene Differentialdiagnose bei der Abklärung eines Tastbefundes
22. Abstract P2-10-03: Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial
23. Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial
24. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
25. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results
26. Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes
27. Androgenrezeptor (AR) und Forkhead BoxA1 (FOXA1) als Prognosefaktoren beim frühen HER2-negativen Mammakarzinom – eine translationale Substudie im Rahmen der prospektiven Phase-III-WSG-Plan B Studie
28. Histologisches Grading beim Mammakarzinom
29. Finale Analyse der WSG-ADAPT HER2+/HR+ Studie: Wirksamkeit und Sicherheit von 12 Wochen T-DM 1 neoadjuvant ± endokrine Therapie (ET) vs. Trastuzumab + ET beim primären Mammakarzinom
30. Vergleich der 12-wöchigen neoadjuvanten Chemotherapie mit Nab-Paclitaxel mit Gemcitabine vs. Carboplatin bei Patientinnen mit triple-negativem Mammakarzinom: ADAPT-TN randomiiserte Phase II Studie
31. Prospektive Phase-III PlanB-Studie: 5 Jahres Daten zum prognostischen Stellenwert von 21-Gen Recurrence-Score, zentralpathologischem Grading, ER, PR, Ki-67 Review beim frühem Hochrisiko HR+/HER2-negativen Mammakarzinom
32. Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer
33. Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial
34. Abstract P2-07-01: Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) – A translational analysis of the prospective WSG planB trial
35. Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial
36. 1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial
37. Luminale Subtypen vs. frühes Proliferationsansprechen in Kombination mit Oncotype DX® beim frühen Mammakarzinom: Beobachtungen aus der WSG-ADAPT HR+/HER2- Substudie
38. Diskordanz der Prognosefaktoren beim frühen Mammakarzinom (Recurrence Score, zentrales Grading, Ki67) und deren Einfluss auf die frühe Rezidivierung in der prospektiven Phase III WSG-planB Studie
39. P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study
40. Oncotype DX® und Proliferationsänderung durch kurzzeitige präoperative endokrine Induktionstherapie zur Therapieentscheidung beim frühen Mammakarzinom: Biomarkerdaten aus der prospektiven multi-zentrischen Phase II/III WSG-ADAPT Studie
41. Oncotype DX® und Proliferationsänderung durch kurzzeitige präoperative endokrine Induktionstherapie zur Therapieentscheidung beim frühen Mammakarzinom: Biomarkerdaten aus der prospektiven multi-zentrischen Phase II/III WSG-ADAPT Studie
42. Stanzbioptische Differenzialdiagnose von Spindelzelltumoren der Mamma
43. Proliferationsbestimmung beim Mammakarzinom durch den immunhistochemischen Nachweis von Ki-67
44. Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine
45. ADAPT - Adjuvante an Dynamischen Markern-Adjustierte Personalisierte Therapie Studie zur Therapie-Individualisierung beim frühem Mammakarzinom - erste Ergebnisse aus dem HR+/HER2- und HR+/HER2+ Subprotokoll
46. Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial
47. Welche Prognosefaktoren sind geeignet für den klinischen Einsatz beim Mammakarzinom? Prospektiver Vergleich von Recurrence Score, uPA/PAI-1, Grading und molekularen Subtypen und Korrelationen aus der WSG-Plan B Studie
48. S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.
49. Abstract P3-10-12: Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer
50. Translationales Forschungsprogramm der planB Studie: Vergleich der anthrazyklinfreien adjuvanten Chemotherapie (6xTC) mit einer Standard-Chemotherapie (4xEC-4xDoc) bei Patientinnen mit Her-2 negativem Mammakarzinom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.